Trials / Active Not Recruiting
Active Not RecruitingNCT07285902
A Study Comparing the Efficacy and Safety of HRS9531 Injection With Semaglutide Injection in Subjects With Obesity
A Multicenter, Randomized, Open-label, Parallel-controlled Phase III Study Comparing the Efficacy and Safety of HRS9531 Injection Versus Semaglutide Injection in Subjects With Obesity
- Status
- Active Not Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 572 (actual)
- Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is a multicenter, randomized, open-label, parallel-controlled, phase III study to compare the efficacy, safety, and tolerability of HRS9531 versus semaglutide once weekly (QW) in adult subjects with obesity
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HRS9531 injection | HRS9531 injection |
| DRUG | Semaglutide Injection | Semaglutide Injection |
Timeline
- Start date
- 2025-12-25
- Primary completion
- 2027-03-01
- Completion
- 2027-03-01
- First posted
- 2025-12-16
- Last updated
- 2026-02-27
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT07285902. Inclusion in this directory is not an endorsement.